Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
CD39 and CD73 in immunity and inflammation
In a statement to Insider, Novo Nordisk, the company that makes Wegovy and Ozempic, said that Gila monsters and the discovery of exendin-4 "did not have anything to do with our decision to develop long-acting GLP-1 receptor agonists" for obesity, because "that was based on GLP-1 biology in humans." But the company also said that "the GLP-1-like effect of exendin-4" in Gila monsters was "an important contribution to the field," as it led to the development of the very first injectable drug of its kind
But one layer deeperat the cellular leveltheres another key player that deserves your attention: glutathione
For example, establishing appropriate clinical trial protocols and approval pathways for organoid-based drug development and therapies represents a significant challenge for regulatory agencies (65)
US$ 27.66
US$ 29.21
US$ 28.45
